Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLRXNASDAQ:BYSINASDAQ:LTRNNASDAQ:SPRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLRXBioLineRx$3.09-2.5%$3.06$2.30▼$35.60$10.29M1.1566,570 shs14,896 shsBYSIBeyondSpring$1.70+1.3%$1.52$0.98▼$3.63$68.58M0.1329,333 shs13,252 shsLTRNLantern Pharma$4.11+3.3%$3.53$2.55▼$6.80$44.33M1.6364,323 shs43,521 shsSPROSpero Therapeutics$0.61-1.6%$0.70$0.51▼$1.69$34.67M0.23184,620 shs144,933 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLRXBioLineRx-2.52%-4.92%+12.36%-8.85%-88.15%BYSIBeyondSpring+1.86%+1.86%+54.64%+2.47%-31.13%LTRNLantern Pharma+3.27%+11.99%+28.04%-13.66%-33.28%SPROSpero Therapeutics-1.61%0.00%+1.67%-25.73%-62.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLRXBioLineRx2.0617 of 5 stars3.33.00.00.02.00.01.3BYSIBeyondSpringN/AN/AN/AN/AN/AN/AN/AN/ALTRNLantern Pharma2.0217 of 5 stars3.53.00.00.02.40.00.6SPROSpero Therapeutics4.1223 of 5 stars3.32.00.04.71.60.02.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLRXBioLineRx 2.50Moderate Buy$26.00741.42% UpsideBYSIBeyondSpring 0.00N/AN/AN/ALTRNLantern Pharma 3.00Buy$25.00508.27% UpsideSPROSpero Therapeutics 2.50Moderate Buy$5.00719.67% UpsideCurrent Analyst Ratings BreakdownLatest LTRN, BLRX, SPRO, and BYSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025BLRXBioLineRxJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/2/2025LTRNLantern PharmaLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.003/31/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $26.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLRXBioLineRx$28.94M0.36N/AN/A$7.30 per share0.42BYSIBeyondSpring$1.88M36.56N/AN/A($0.91) per share-1.87LTRNLantern PharmaN/AN/AN/AN/A$3.76 per shareN/ASPROSpero Therapeutics$27.40M1.24$0.38 per share1.62$2.02 per share0.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLRXBioLineRx-$60.61M-$8.80N/AN/AN/A-90.57%-163.37%-34.21%5/27/2025 (Estimated)BYSIBeyondSpring-$21.03MN/A0.00∞N/AN/AN/AN/AN/ALTRNLantern Pharma-$15.96M-$1.93N/AN/AN/AN/A-56.91%-51.17%5/15/2025 (Estimated)SPROSpero Therapeutics$22.81M-$1.278.72N/AN/A3.30%4.03%2.21%5/13/2025 (Estimated)Latest LTRN, BLRX, SPRO, and BYSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2025Q1 2025BLRXBioLineRx-$0.84N/AN/AN/A$7.72 millionN/A5/21/2025Q1 2025SPROSpero Therapeutics-$0.44N/AN/AN/AN/AN/A5/15/2025Q1 2025LTRNLantern Pharma-$0.49N/AN/AN/AN/AN/A5/12/2025N/ABYSIBeyondSpringN/A-$0.06N/A$0.11N/AN/A3/27/2025Q4 2024LTRNLantern Pharma-$0.51-$0.54-$0.03-$0.54N/AN/A3/27/2025Q4 2024SPROSpero Therapeutics-$0.35-$0.38-$0.03-$0.38$12.40 million$15.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLRXBioLineRxN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/ALTRNLantern PharmaN/AN/AN/AN/AN/ASPROSpero Therapeutics$0.069.84%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLRXBioLineRx2.111.521.37BYSIBeyondSpringN/A1.82N/ALTRNLantern PharmaN/A8.318.31SPROSpero TherapeuticsN/A2.682.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLRXBioLineRx1.56%BYSIBeyondSpring40.29%LTRNLantern Pharma28.62%SPROSpero Therapeutics25.60%Insider OwnershipCompanyInsider OwnershipBLRXBioLineRx1.10%BYSIBeyondSpring29.31%LTRNLantern Pharma7.31%SPROSpero Therapeutics4.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLRXBioLineRx403.33 million3.29 millionOptionableBYSIBeyondSpring8040.32 million27.59 millionOptionableLTRNLantern Pharma2010.79 million10.00 millionOptionableSPROSpero Therapeutics15055.91 million52.05 millionOptionableLTRN, BLRX, SPRO, and BYSI HeadlinesRecent News About These CompaniesSpero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025May 5, 2025 | globenewswire.comSpero Therapeutics, Inc.: Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive OfficerApril 29, 2025 | finanznachrichten.deSpero Therapeutics Appoints Esther Rajavelu as President and Chief Executive OfficerApril 28, 2025 | globenewswire.comSpero Therapeutics Analyst RatingsApril 7, 2025 | benzinga.comTD Cowen Sticks to Their Hold Rating for Spero Therapeutics (SPRO)April 2, 2025 | markets.businessinsider.comWe're Keeping An Eye On Spero Therapeutics' (NASDAQ:SPRO) Cash Burn RateMarch 29, 2025 | finance.yahoo.comSpero Therapeutics reports Q4 EPS (38c), consensus (31c)March 28, 2025 | markets.businessinsider.comSpero halts development on another antibiotic in latest reprioritizationMarch 28, 2025 | fiercebiotech.comSpero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business UpdateMarch 28, 2025 | finanznachrichten.deSpero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comSpero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue EstimatesMarch 27, 2025 | zacks.comSpero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business UpdateMarch 27, 2025 | globenewswire.com1SPRO : A Glimpse of Spero Therapeutics's Earnings PotentialMarch 26, 2025 | benzinga.comSpero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025March 18, 2025 | globenewswire.comUPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | globenewswire.comSpero Therapeutics to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | globenewswire.comSpero Therapeutics CEO sells shares worth $121,159February 6, 2025 | msn.comSpero Therapeutics, Inc. (NASDAQ:SPRO) CFO Esther Rajavelu Sells 20,689 SharesFebruary 6, 2025 | insidertrades.comSpero therapeutics CFO sells $16,137 in stockFebruary 6, 2025 | msn.comSpero Therapeutics COO Timothy Keutzer sells shares for $44,097February 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLTRN, BLRX, SPRO, and BYSI Company DescriptionsBioLineRx NASDAQ:BLRX$3.09 -0.08 (-2.52%) Closing price 05/12/2025 03:51 PM EasternExtended Trading$3.16 +0.07 (+2.14%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.BeyondSpring NASDAQ:BYSI$1.63 -0.05 (-2.92%) As of 05/12/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Lantern Pharma NASDAQ:LTRN$4.11 +0.13 (+3.27%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$3.84 -0.27 (-6.45%) As of 05/12/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Spero Therapeutics NASDAQ:SPRO$0.61 -0.01 (-1.61%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$0.64 +0.03 (+4.75%) As of 05/12/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
